Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

NCT00150384 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Dyslipidemia

Interventions

DRUG: Amlodipine/Atorvastatin

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.